Inhibition of amyloid precursor protein processing enhances gemcitabine-mediated cytotoxicity in pancreatic cancer cells

Journal of Biological Chemistry

Volumn 288, Issue 42, 2013, Pages 30114-30124

  Woods, Neha Kabra ^a,b   Padmanabhan, Jaya ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEINS; CANCER CELLS; GEMCITABINE; PANCREATIC CANCERS; SECRETASES;

CELL GROWTH; GLYCOPROTEINS;

CELLS;

ADAM10 ENDOPEPTIDASE; AMYLOID PRECURSOR PROTEIN; AMYLOID PRECURSOR PROTEIN ALPHA; BATIMASTAT; GEMCITABINE; GI 254023X; METALLOPROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION;

ADAM ADAMTS; AMYLOID PRECURSOR PROTEIN; PANCREATIC CANCER; PROTEIN SECRETION; SECRETASES;

ADAM PROTEINS; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXINS; DEOXYCYTIDINE; DIPEPTIDES; HUMANS; HYDROXAMIC ACIDS; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PHENYLALANINE; PROTEASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; THIOPHENES;

EID: 84886938358     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.459255     Document Type: Article

References (36)

1. Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010) Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300
2. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., and Thun, M. J. (2009) Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249
3. Burris, H. A., 3rd, Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., Nelson, R., Dorr, F. A., Stephens, C. D., and Von Hoff, D. D. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403-2413
4. Berlin, J., and Benson, A. B., 3rd. (2010) Chemotherapy: Gemcitabine remains the standard of care for pancreatic cancer. Nat. Rev. Clin. Oncol. 7, 135-137
5. Berlin, J. D., Catalano, P., Thomas, J. P., Kugler, J. W., Haller, D. G., and Benson, A. B., 3rd. (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. 20, 3270-3275
6. Rocha Lima, C. M., Green, M. R., Rotche, R., Miller, W. H., Jr., Jeffrey, G. M., Cisar, L. A., Morganti, A., Orlando, N., Gruia, G., and Miller, L. L. (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol. 22, 3776-3783
7. Oettle, H., Richards, D., Ramanathan, R. K., van Laethem, J. L., Peeters, M., Fuchs, M., Zimmermann, A., John, W., Von Hoff, D., Arning, M., and Kindler, H. L. (2005) A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann. Oncol. 16, 1639-1645
8. Van Cutsem, E., Verslype, C., and Grusenmeyer, P. A. (2007) Lessons learned in the management of advanced pancreatic cancer. J. Clin. Oncol. 25, 1949-1952
9. Hansel, D. E., Rahman, A., Wehner, S., Herzog, V., Yeo, C. J., and Maitra, A. (2003) Increased expression and processing of the Alzheimer amyloid precursor protein in pancreatic cancer may influence cellular proliferation. Cancer Res. 63, 7032-7037
10. Venkataramani, V., Rossner, C., Iffland, L., Schweyer, S., Tamboli, I. Y., Walter, J., Wirths, O., and Bayer, T. A. (2010) Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein. J. Biol. Chem. 285, 10678 -10689
11. Lewis, D. A., Higgins, G. A., Young, W. G., Goldgaber, D., Gajdusek, D. C., Wilson, M. C., and Morrison, J. H. (1988) Distribution of precursor amyloid- beta-protein messenger RNA in human cerebral cortex: relationship to neurofibrillary tangles and neuritic plaques. Proc. Natl. Acad. Sci. U.S.A. 85, 1691-1695
12. Perry, G., Lipphardt, S., Mulvihill, P., Kancherla, M., Mijares, M., Gambetti, P., Sharma, S., Maggiora, L., Cornette, J., and Lobl, T. (1988) Amyloid precursor protein in senile plaques of Alzheimer disease. Lancet 2, 746
13. De Strooper, B., and Annaert, W. (2000) Proteolytic processing and cell biological functions of the amyloid precursor protein. J. Cell Sci. 113, 1857-1870
14. Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosinski, M. A., Biere, A. L., Curran, E., Burgess, T., Louis, J. C., Collins, F., Treanor, J., Rogers, G., and Citron, M. (1999) β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741
15. Gandy, S., Caporaso, G., Buxbaum, J., Frangione, B., and Greengard, P. (1994) APP processing, A β-amyloidogenesis, and the pathogenesis of Alzheimer's disease. Neurobiol. Aging 15, 253-256
16. Lammich, S., Kojro, E., Postina, R., Gilbert, S., Pfeiffer, R., Jasionowski, M., Haass, C., and Fahrenholz, F. (1999) Constitutive and regulated α-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc. Natl. Acad. Sci. U.S.A. 96, 3922-3927
17. Prinzen, C., Trümbach, D., Wurst, W., Endres, K., Postina, R., and Fahrenholz, F. (2009) Differential gene expression in ADAM10 and mutant ADAM10 transgenic mice. BMC Genomics 10, 66
18. Kuhn, P. H., Wang, H., Dislich, B., Colombo, A., Zeitschel, U., Ellwart, J. W., Kremmer, E., Rossner, S., and Lichtenthaler, S. F. (2010) ADAM10 is the physiologically relevant, constitutive -secretase of the amyloid precursor protein in primary neurons. EMBO J. 29, 3020-3032
19. Lopez-Perez, E., Zhang, Y., Frank, S. J., Creemers, J., Seidah, N., and Checler, F. (2001) Constitutive -secretase cleavage of the -amyloid precursor protein in the furin-deficient LoVo cell line: involvement of the prohormone convertase 7 and the disintegrin metalloprotease ADAM10. J. Neurochem. 76, 1532-1539
20. Buxbaum, J. D., Liu, K. N., Luo, Y., Slack, J. L., Stocking, K. L., Peschon, J. J., Johnson, R. S., Castner, B. J., Cerretti, D. P., and Black, R. A. (1998) Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated -secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem. 273, 27765-27767
21. Kohutek, Z. A., diPierro, C. G., Redpath, G. T., and Hussaini, I. M. (2009) ADAM-10-mediated N-cadherin cleavage is protein kinase C-α-dependent and promotes glioblastoma cell migration. J. Neurosci. 29, 4605- 4615
22. Maretzky, T., Reiss, K., Ludwig, A., Buchholz, J., Scholz, F., Proksch, E., de Strooper, B., Hartmann, D., and Saftig, P. (2005) ADAM10 mediates Ecadherin shedding and regulates epithelial cell-cell adhesion, migration, and β-catenin translocation. Proc. Natl. Acad. Sci. U.S.A. 102, 9182-9187
23. van Tetering, G., van Diest, P., Verlaan, I., van der Wall, E., Kopan, R., and Vooijs, M. (2009) Metalloprotease ADAM10 is required for Notch1 site 2 cleavage. J. Biol. Chem. 284, 31018-31027
24. Vincent, B., and Govitrapong, P. (2011) Activation of the α-secretase processing of AβPP as a therapeutic approach in Alzheimer's disease. J. Alzheimers Dis. 24, 75-94
25. Postina, R., Schroeder, A., Dewachter, I., Bohl, J., Schmitt, U., Kojro, E., Prinzen, C., Endres, K., Hiemke, C., Blessing, M., Flamez, P., Dequenne, A., Godaux, E., van Leuven, F., and Fahrenholz, F. (2004) A disintegrin- metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J. Clin. Invest. 113, 1456-1464
26. Gaida, M. M., Haag, N., Günther, F., Tschaharganeh, D. F., Schirmacher, P., Friess, H., Giese, N. A., Schmidt, J., and Wente, M. N. (2010) Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma. Int. J. Mol. Med. 26, 281-288
27. Schmitz, A., Tikkanen, R., Kirfel, G., and Herzog, V. (2002) The biological role of the Alzheimer amyloid precursor protein in epithelial cells. Histochem. Cell Biol. 117, 171-180
28. Hundhausen, C., Misztela, D., Berkhout, T. A., Broadway, N., Saftig, P., Reiss, K., Hartmann, D., Fahrenholz, F., Postina, R., Matthews, V., Kallen, K. J., Rose-John, S., and Ludwig, A. (2003) The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102, 1186-1195
29. Arima, T., Enokida, H., Kubo, H., Kagara, I., Matsuda, R., Toki, K., Nishimura, H., Chiyomaru, T., Tatarano, S., Idesako, T., Nishiyama, K., and Nakagawa, M. (2007) Nuclear translocation of ADAM-10 contributes to the pathogenesis and progression of human prostate cancer. Cancer Science 98, 1720-1726
30. McCulloch, D. R., Akl, P., Samaratunga, H., Herington, A. C., and Odorico, D. M. (2004) Expression of the disintegrin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone, insulin-like growth factor I, and epidermal growth factor in the prostate cancer cell model LNCaP. Clinical Cancer Research 10, 314-323
31. Zimmermann, M., Gardoni, F., Marcello, E., Colciaghi, F., Borroni, B., Padovani, A., Cattabeni, F., and Di Luca, M. (2004) Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J. Neurochem. 90, 1489-1499
32. Esch, F. S., Keim, P. S., Beattie, E. C., Blacher, R. W., Culwell, A. R., Oltersdorf, T., McClure, D., and Ward, P. J. (1990) Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 248, 1122-1124
33. Jäger, S., Leuchtenberger, S., Martin, A., Czirr, E., Wesselowski, J., Dieckmann, M., Waldron, E., Korth, C., Koo, E. H., Heneka, M., Weggen, S., and Pietrzik, C. U. (2009) α-secretase mediated conversion of the amyloid precursor protein derived membrane stub C99 to C83 limits Aα generation. J. Neurochem. 111, 1369-1382
34. Furukawa, K., Sopher, B. L., Rydel, R. E., Begley, J. G., Pham, D. G., Martin, G. M., Fox, M., and Mattson, M. P. (1996) Increased activity-regulating and neuroprotective efficacy ofα-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J. Neurochem. 67, 1882-1896
35. Mattson, M. P. (1997) Cellular actions ofα-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol. Rev. 77, 1081-1132
36. Demars, M. P., Bartholomew, A., Strakova, Z., and Lazarov, O. (2011) Soluble amyloid precursor protein: a novel proliferation factor of adult progenitor cells of ectodermal and mesodermal origin. Stem Cell Res. Ther. 2, 36